Volume 111
May. 2023

Whitewashing the Fourth Amendment

by Daniel S. Harawa
A conventional critical race critique of the Supreme Court and its Fourth Amendment jurisprudence is that it erases race. Scholars argue that by erasing race, the Court has crafted doctrine that is oblivious to people of color’s lived experiences with policing in America. This Article complicates this critique by asking whether it is solely the […]

Immigration Law’s Missing Presumption

by Fatma Marouf
The presumption of innocence is a foundational concept in criminal law but is completely missing from quasi-criminal immigration proceedings. This Article explores the relevance of a presumption of innocence to removal proceedings, arguing that immigration law has been designed and interpreted in ways that disrupt formulating any such presumption to facilitate deportation. The Article examines […]

The Abolition of Food Oppression

by Etienne C. Toussaint
Public health experts trace the heightened risk of mortality from COVID-19 among historically marginalized populations to their high rates of diabetes, asthma, and hypertension, among other diet-related comorbidities. However, food justice activists call attention to structural oppression in global food systems, perhaps best illuminated by the prevalence of unhealthy fast-food restaurants (and the lack of […]

The Racialized Violence of Police Canine Force

by Madalyn K. Wasilczuk
Two white men stand over a screaming Black teenager. A dog bites into the boy’s arm, thrashing its head back and forth, as the men egg the dog on, “Get ‘im, boy. Get ‘im.” The teenager heaves deep sobs, begging them to release him from the dog’s jaws. It is 2019, and I am sitting […]

Don’t Take the Blue Pill: A Law and Political Economy (LPE) Critique of the Pharmaceutical Industry

by Daniel Whittam
In February 2019, the Senate Committee on Finance summoned top executives from seven large pharmaceutical corporations for a hearing on drug pricing in America.The hearing, one of several conducted on similar subjects by Congress in the past decade, reflected widespread, even bipartisan, frustration with rising government spending on pharmaceutical products. The CEOs were predictably on […]